Press Room

Press Clipping / Sep 23, 2020

Hovione to support production of antiviral Veklury for COVID-19

Manufacturing Chemist, September 23, 2020

Hovione has signed a partnership agreement with Ligand to significantly ramp up the production output of Captisol

Captisol, a Ligand product, is a chemically modified cyclodextrin proven to improve the solubility and stability of drugs.

It is used in the formulation of Gilead’s Covid-19 treatment Veklury (remdesivir). Hovione is the sole producer of this key enabling excipient.

The COVID-19 pandemic has, to date, killed one million people; studies show that in the next 3 months cumulative deaths may more than double.

“To meet Captisol demand associated with Veklury, Hovione will soon be producing per month the quantity it usually produces in one year. This sudden spike in demand has required unique mobilisation efforts across the Hovione network to secure additional raw material supply, execute major capital expenditure projects at our sites, maximise operational efficiency, hire additional talent and identify external partners to expand our overall capacity."

"The pharmaceutical supply chain is working together in an unprecedented fashion to treat patients and save lives. Hovione is privileged to be part of this truly global response,” said Jean-Luc Herbeaux, Chief Operating Officer.

“Ligand values its longstanding partnership with Hovione,” said Matt Foehr, President and Chief Operating Officer of Ligand.

“Their excellent customer service, global commitment to quality and high pharmaceutical standards make them an ideal partner for Captisol, a critical component for a number of life-saving medicines."

"We commend them for responsibly and efficiently partnering with Ligand to manage the scale up and expansion of their operations to contribute to global health during the pandemic.”

 

Read the article on Manufacturing Chemist website

 

Also in the Press Room

See All

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025